news
VTP50469, a new targeted therapy for MLL-rearranged leukaemia, shows greater…
12 December 2019 | By Hannah Balfour (Drug Target Review)
VTP50469, a new targeted therapy for MLL-rearranged leukaemia, shows greater efficacy and fewer side-effects in mice, according to new research.